About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2024№11
Mental health and sexual function...

Mental health and sexual function in women with premature ovarian insufficiency

DOI
https://dx.doi.org/10.18565/aig.2024.188

Kolpakova T.G., Kochergina M.S., Averkova V.G., Yureneva S.V., Samushiya M.A.

1) Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia; 2) Central State Medical Academy, Administrative Directorate of the President of the Russian Federation, Moscow, Russia

The present review is an analysis of the current foreign and Russian literature on the problem of premature ovarian insufficiency (POI). The article provides a general overview of the etiological factors involved in disease development and the specific characteristics of the clinical picture. POI is associated with a negative impact on mood, sleep and general wellbeing and has a significant impact on quality of life, particularly on the psycho-emotional sphere and sexual function of women. The article addresses several key issues related to the impact of stress on ovarian function, the prevalence of psycho-emotional disorders among women with POI, the relationship between androgen concentration and sexual function, as well as the results of androgen therapy, according to the findings of foreign scientific publications. The paper considers the value of developing a systematic, multidisciplinary approach to the management of women with POI, which can lead to a significant improvement in their quality of life.
Conclusion: Psychological support through counselling is compulsory. Further studies are required to evaluate the efficacy and safety of testosterone therapies and to determine optimal dosages for patients with POI. This will assist in the development of an optimized treatment approach.

Authors’ contributions: Yureneva S.V., Samushiya M.A. – developing the concept and design of the study, analysis of scientific material, editing the text; Kolpakova T.G., Averkova V.G. – collecting and processing the material; Kolpakova T.G., Kochergina M.S. – writing the text. All authors made equivalent contributions to the preparation of the publication.
Conflicts of interest: Authors declare lack of the possible conflicts of interests.
Funding: The study was conducted without sponsorship.
For citation: Kolpakova T.G., Kochergina M.S., Averkova V.G., Yureneva S.V., Samushiya M.A. 
Mental health and sexual function in women with premature ovarian insufficiency.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2024; (11): 34-39 (in Russian)
https://dx.doi.org/10.18565/aig.2024.188

Keywords

premature ovarian insufficiency
POI
sexual function
androgens
testosterone
mental health
stress
anxiety
depression
Full text (in Russian)

References

  1. Golezar S., Ramezani Tehrani F., Khazaei S., Ebadi A., Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019; 22(4): 403-11. https://dx.doi.org/10.1080/13697137.2019.1574738.
  2. Rossetti R., Ferrari I., Bonomi M., Persani L. Genetics of primary ovarian insufficiency. Clin Genet. 2017; 91(2):183-98. https://dx.doi.org/10.1111/cge.12921.
  3. Денисова В.М., Ярмолинская М.И., Закураева К.А. Преждевременная недостаточность яичников: генетические причины и тактика ведения пациенток (обзор литературы). Журнал акушерства и женских болезней. 2021; 70(3): 75-91. [Denisova V.M., Yarmolinskaya M.I., Zakuraeva K.A. Premature ovarian insufficiency: genetic causes and treatment options. A literature review. Journal of Obstetrics and Women's Diseases. 2021; 70(3): 75-91. (in Russian)]. https://dx.doi.org/10.17816/JOWD59987.
  4. Щагина О.А., Демина Н.А., Бессонова Л.А., Бескоровайная Т.С., Поляков А.В. Мутации гена FOXL2 при синдроме «Блефарофимоз-птоз-обратный эпикант». Медицинская генетика. 2019; 18(8): 17-20. [Shchagina O.A., Demina N.A., Bessonova L.A., Beskorovainaya T.S., Polyakov A.V. FOXL2 mutations in Blepharophimosis-Ptosis-Epicanthus inversus syndrome. Medical Genetics. 2019; 18(8): 17-20. (in Russian)]. https://dx.doi.org/10.25557/2073-7998.2019.08.17-20.
  5. BMS Consensus Statement. Premature ovarian insufficiency (POI). 2023.
  6. Kirshenbaum M., Orvieto R. Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal. J. Assist. Reprod. Genet. 2019; 36(11): 2207-15. https://dx.doi.org/10.1007/s10815-019-01572-0.
  7. Адамян Л.В., Пивазян Л.Г., Антонова А.А. Преждевременная недостаточность яичников и аутоиммунитет: есть ли взаимосвязь? Проблемы репродукции. 2022; 28(6): 116-24. [Adamyan L.V., Pivazyan L.G., Antonova A.A. Autoimmunity and premature ovarian insufficiency — up-to-date. Russian Journal of Human Reproduction. 2022; 28(6): 116-24. (in Russian)]. https://dx.doi.org/10.17116/repro202228061116 .
  8. Ishizuka B. Current understanding of the etiology, symptomatology, and treatment options in premature ovarian insufficiency (POI). Front. Endocrinol. (Lausanne). 2021; 12: 626924. https://dx.doi.org/10.3389/fendo.2021.626924.
  9. Panay N., Anderson R.A., Nappi R.E., Vincent A.J., Vujovic S., Webber L. et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020; 23(5):426-46. https://dx.doi.org/10.1080/13697137.2020.1804547.
  10. Wang Y., Jiang J., Zhang J., Fan P., Xu J. Research progress on the etiology and treatment of premature ovarian insufficiency. Biomed. Hub. 2023; 8(1): 97-107. https://dx.doi.org/10.1159/000535508.
  11. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum. Reprod. 2016; 31(5): 926-37. https://dx.doi.org/10.1093/humrep/dew027.
  12. Lumsden M.A. The NICE Guideline – Menopause: diagnosis and management. Climacteric. 2016; 19(5): 426-9. https://dx.doi.org/10.1080/13697137.2016.1222483.
  13. Baber R.J., Panay N., Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://dx.doi.org/10.3109/13697137.2015.1129166.
  14. Chon S.J., Umair Z., Yoon M.S. Premature ovarian insufficiency: past, present, and future. Front. Cell. Dev. Biol. 2021; 9: 672890. https://dx.doi.org/10.3389/fcell.2021.672890.
  15. Torrealday S., Kodaman P., Pal L. Premature ovarian insufficiency - an update on recent advances in understanding and management. F1000Research. 2017; 6: 2069. https://dx.doi.org/10.12688/f1000research.11948.1.
  16. Podfigurna-Stopa A., Czyzyk A., Grymowicz M., Smolarczyk R., Katulski K., Czajkowski K. et al. Premature ovarian insufficiency: the context of long-term effects. J. Endocrinol. Invest. 2016; 39(9): 983-90. https://dx.doi.org/10.1007/s40618-016-0467-z.
  17. Upton C.E., Daniels J.P., Davies M.C. Premature ovarian insufficiency: the need for evidence on the effectiveness of hormonal therapy. Climacteric. 2021; 24(5): 453-8. https://dx.doi.org/10.1080/13697137.2021.1902496.
  18. Kapoor E. Primary ovarian insufficiency: a toolkit for the busy clinician. Menopause. 2024; 31(1): 65-7. https://dx.doi.org/10.1097/GME.0000000000002275.
  19. Shelling A.N., Ahmed Nasef N. The role of lifestyle and dietary factors in the development of premature ovarian insufficiency. Antioxidants. 2023; 12(8): 1601. https://dx.doi.org/10.3390/antiox12081601.
  20. Prasad S., Tiwari M., Pandey A.N., Shrivastav T.G., Chaube S.K. Impact of stress on oocyte quality and reproductive outcome. J. Biomed. Sci. 2016; 23(1): 36. https://dx.doi.org/10.1186/s12929-016-0253-4.
  21. Fu X.Y., Chen H.H., Zhang N., Ding M.X., Qiu Y.E., Pan X.M. et al. Effects of chronic unpredictable mild stress on ovarian reserve in female rats: Feasibility analysis of a rat model of premature ovarian failure. Mol. Med. Rep. 2018; 18(1): 532-40. https://dx.doi.org/10.3892/mmr.2018.8989.
  22. Sun J., Fan Y., Guo Y., Pan H., Zhang C., Mao G. et al. Chronic and cumulative adverse life events in women with primary ovarian insufficiency: an exploratory qualitative study. Front. Endocrinol (Lausanne). 2022; 13. https://dx.doi.org/10.3389/fendo.2022.856044.
  23. Gava G., Orsili I., Alvisi S., Mancini I., Seracchioli R., Meriggiola M.C. Cognition, mood and sleep in menopausal transition: the role of menopause hormone therapy. Medicina (B Aires). 2019; 55(10): 668. https://dx.doi.org/10.3390/medicina55100668.
  24. Engberg H., Strandqvist A., Nordenström A., Butwicka A., Nordenskjöld A., Hirschberg A.L. et al. Increased psychiatric morbidity in women with complete androgen insensitivity syndrome or complete gonadal dysgenesis. J. Psychosom. Res. 2017; 101: 122-7. https://dx.doi.org/10.1016/j.jpsychores.2017.08.009.
  25. Słopień R. Mood disorders in women with premature ovarian insufficiency. Menopausal. Rev. 2018; 17(3): 124-6. https://dx.doi.org/10.5114/pm.2018.78556.
  26. Golezar S., Keshavarz Z., Ramezani Tehrani F., Ebadi A., Zayeri F., Golezar M.H. Primary ovarian insufficiency quality of life scale (POIQOLS): development and psychometric properties. BMC Womens Health. 2022; 22(1): 481. https://dx.doi.org/10.1186/s12905-022-02008-1.
  27. Xi D., Chen B., Tao H., Xu Y., Chen G. The risk of depressive and anxiety symptoms in women with premature ovarian insufficiency: a systematic review and meta-analysis. Arch. Womens Ment. Health. 2023; 26(1): 1-10. https://dx.doi.org/10.1007/s00737-022-01289-7.
  28. Schmidt P.J., Luff J.A., Haq N.A., Vanderhoof V.H., Koziol D.E., Calis K.A. et al. Depression in women with spontaneous 46, XX primary ovarian insufficiency. J. Clin. Endocrinol. Metab. 2011; 96(2): E278-87. https://dx.doi.org/10.1210/jc.2010-0613.
  29. Allshouse A.A., Semple A.L., Santoro N.F. Evidence for prolonged and unique amenorrhea-related symptoms in women with premature ovarian failure/primary ovarian insufficiency. Menopause. 2015; 22(2):166-74. https://dx.doi.org/10.1097/GME.0000000000000286.
  30. Аверкова В.Г., Юренева С.В. Оценка качества жизни пациенток с преждевременной недостаточностью яичников, принимающих заместительную гормональную терапию. Акушерство и гинекология. 2023; 5: 50-8. [Averkova V.G., Yureneva S.V. Quality of life in patients with premature ovarian insufficiency treated with hormone replacement therapy. Obstetrics and Gynecology. 2023; (5): 50-8 (in Russian)]. https://dx.doi.org/10.18565/aig.2023.16.
  31. Maciejewska-Jeske M., Szeliga A., Męczekalski B. Consequences of premature ovarian insufficiency on women’s sexual health. Menopausal. Rev. 2018; 17(3): 127-30. https://dx.doi.org/10.5114/pm.2018.78557.
  32. Nappi R.E., Cucinella L., Martini E., Rossi M., Tiranini L., Martella S. et al. Sexuality in premature ovarian insufficiency. Climacteric. 2019; 22(3): 289-95. https://dx.doi.org/10.1080/13697137.2019.1575356.
  33. Calik-Ksepka A., Grymowicz M., Rudnicka E., Skórska J., Machura P., Pięta W. et al. Signs and symptoms, evaluation, and management of genitourinary tract consequences of premature ovarian insufficiency. Menopausal. Rev. 2018; 17(3): 131-4. https://dx.doi.org/10.5114/pm.2018.78558.
  34. Paschou S.A., Athanasiadou K.I., Hafford-Letchfield T., Hinchliff S., Mauskar M., Rees M. et al. Sexual health and wellbeing and the menopause: An EMAS clinical guide. Maturitas. 2024; 189: 108055. https://dx.doi.org/10.1016/j.maturitas.2024.108055.
  35. Javadpour S., Sharifi N., Mosallanezhad Z., Rasekhjahromi A., Jamali S. Assessment of premature menopause on the sexual function and quality of life in women. Gynecol. Endocrinol. 2021; 37(4): 307-11. https://dx.doi.org/10.1080/09513590.2021.1871894.
  36. Yela D.A., Soares P.M., Benetti-Pinto C.L. Influence of sexual function on the social relations and quality of life of women with premature ovarian insufficiency. Rev. Bras. Ginecol. Obstet. 2018; 40(2): 66-71. https://dx.doi.org/10.1055/s-0037-1615289.
  37. Blümel J.E., Chedraui P., Vallejo M.S., Dextre M., Elizalde A., Escalante C. et al. Genitourinary symptoms and sexual function in women with primary ovarian insufficiency. Climacteric. 2024; 27(3): 269-74. https://dx.doi.org/10.1080/13697137.2024.2306278.
  38. Soman M., Huang L.C., Cai W.H., Xu J.B., Chen J.Y., He R.K. et al. Serum androgen profiles in women with premature ovarian insufficiency: a systematic review and meta-analysis. Menopause. 2019; 26(1): 78-93. https://dx.doi.org/10.1097/GME.0000000000001161.
  39. Табеева Г.И., Марченко Л.А., Карселадзе А.И., Бутарева Л.А., Строганова А.М. Роль гена андрогенного рецептора в генезе преждевременной недостаточности яичников. Акушерство и гинекология. 2011; 6: 36-41. [Tabeyeva G.I., Marchenko L.A., Karseladze A.I., Butareva L.A., Stroganova A.M. Role of the androgen-receptor gene in the genesis of premature ovarian failure. Obstetrics and Gynecology. 2011; (6): 36-41. (in Russian)].
  40. Zheng J., Islam R.M., Skiba M.A., Bell R.J., Davis S.R. Associations between androgens and sexual function in premenopausal women: a cross-sectional study. Lancet Diabetes Endocrinol. 2020; 8(8): 693-702. https://dx.doi.org/10.1016/S2213-8587(20)30239-4.
  41. Гависова А.А., Киндышева С.В., Стародубцева Н.Л., Франкевич В.Е., Долгушина Н.В. Андрогенный профиль у женщин с бесплодием в программах вспомогательных репродуктивных технологий в зависимости от овариального ответа. Акушерство и гинекология. 2022; 10: 129-37. [Gavisova A.A., Kindysheva S.V., Starodubtseva N.L., Frankevich V.E., Dolgushina N.V. Androgen profile in infertile women undergoing treatment with assisted reproductive technologies depending on the ovarian response. Obstetrics and Gynecology. 2022; (10): 129-37. (in Russian)]. https://dx.doi.org/10.18565/aig.2022.10.129-137.
  42. Davis S.R. Androgens in premenopausal women and women with premature ovarian insufficiency. Climacteric. 2021; 24(5):459-65. https://dx.doi.org/10.1080/13697137.2020.1866530.
  43. Davis S.R., Wahlin-Jacobsen S. Testosterone in women—the clinical significance. Lancet Diabetes Endocrinol. 2015; 3(12): 980-92. https://dx.doi.org/10.1016/S2213-8587(15)00284-3.
  44. van Zwol-Janssens C., Jiskoot G., Schipper J., Louwers Y.V. Introducing a value-based healthcare approach for women with premature ovarian insufficiency (POI): Recommendations for patient-centered outcomes in clinical practice. Maturitas. 2024; 184: 107971. https://dx.doi.org/10.1016/j.maturitas.2024.107971.
  45. Meziou N., Scholfield C., Taylor C.A., Armstrong H.L. Hormone therapy for sexual function in perimenopausal and postmenopausal women: a systematic review and meta-analysis update. Menopause. 2023; 30(6): 659-71. https://dx.doi.org/10.1097/GME.0000000000002185.
  46. Singer D., Mann E., Hunter M.S., Pitkin J., Panay N. The silent grief: psychosocial aspects of premature ovarian failure. Climacteric. 2011; 14(4): 428-37. https://dx.doi.org/10.3109/13697137.2011.571320.
  47. Davis S.R., Baber R., Panay N., Bitzer J., Perez S.C., Islam R.M. et al. Global Consensus Position Statement on the use of testosterone therapy for women. J. Clin. Endocrinol. Metab. 2019; 104(10): 4660-6. https://dx.doi.org/10.1210/jc.2019-01603.
  48. Achilli C., Pundir J., Ramanathan P., Sabatini L., Hamoda H., Panay N. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil. Steril. 2017; 107(2): 475-482.e15. https://dx.doi.org/10.1016/j.fertnstert.2016.10.028.
  49. Guerrieri G.M., Martinez P.E., Klug S.P., Haq N.A., Vanderhoof V.H., Koziol D.E. et al. Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. Menopause. 2014; 21(9): 952-61. https://dx.doi.org/10.1097/GME.0000000000000195.

Received 01.08.2024

Accepted 12.11.2024

About the Authors

Tamara G. Kolpakova, PhD student at the Department of Gynecological Endocrinology, obstetrician-gynecologist, Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, 117997, Russia, Moscow, Oparin str., 4, +7(965)245-59-66, toma-di@yandex.ru,
https://orcid.org/0000-0002-8071-5713
Maria S. Kochergina, Resident at the Department of Psychiatry, psychiatrist, Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation, 121359, Russia, Moscow, Marshal Timoshenko str., 19/1A, +7(916)743-74-99, mariakochergina.s@gmail.com, https://orcid.org/0000-0001-5011-539X
Viktoriya G. Averkova, PhD student at the Department of Gynecological Endocrinology, obstetrician-gynecologist, Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, 117997, Russia, Moscow, Oparin str., 4, +7(915)259-08-10, buch1202@mail.ru,
https://orcid.org/0000-0002-8584-5517
Svetlana V. Yureneva, Dr. Med. Sci., Professor, Deputy Director for Research of the Institute of Gynecologic Oncology and Mammology, Professor at the Department of Obstetrics and Gynecology of the Department of Vocational Education, Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, 117997, Russia, Moscow, Oparin str., 4, +7(916)179-74-00, syureneva@gmail.com, https://orcid.org/0000-0003-2864-066X
Marina A. Samushiya, Dr. Med. Sci., Professor, Vice-Rector for Scientific Work, Head of the Department of Psychiatry, psychiatrist, psychotherapist, Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation, 121359, Russia, Moscow, Marshal Timoshenko str., 19/1A, +7(916)277-17-71,
sma-psychiatry@mail.ru, https://orcid.org/0000-0003-3681-9977
Corresponding author: Tamara G. Kolpakova, toma-di@yandex.ru

Similar Articles

№12 / 2021
Smetnik A.A., Rodionov V.V., Kometova V.V., Burmenskaya O.V., Dardyk M.V., Sencha A.N., Ermakova E.I., Ashrafyan L.A.
The breast and sex hormones
№11 / 2024
Menzhinskaya I.V., Pavlovich S.V., Melkumyan A.G., Chuprynin V.D.
A profile of autoantibodies to steroid hormones and steroidogenic enzymes in women with endometriosis
№11 / 2022
Chausov A.A., Gavisova A.A., Dolgushina N.V., Nazarenko T.A., Gardanova Zh.R.
Development and validation of a questionnaire for assessing androgen deficiency in women (FAD – Female Androgen Deficiency) of reproductive age
№4 / 2024
Dubrovina S.O.
Characteristics of consultations for patients aged over 45 years
№8 / 2023
Pshenisnova I.V., Yakovlev P.P.
Androgen priming in a poor ovarian stimulation response
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.